Dr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New York discuss current BRCA1/2 genetic testing practices and the clinical management of localized breast cancer with alterations in these genes.

CME information and select publications here.

Drs Terence Friedlander, Matthew D Galsky, Neeraj Agarwal, Andrew J Armstrong and Elisabeth I Heath discuss recent updates on available and novel treatment strategies for bladder cancer and prostate cancer.

CME information and select publications here.

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.

CME information and select publications here.

Dr John Bridgewater from the UCL Cancer Institute in London, United Kingdom, discusses patient cases and summarizes current treatment approaches for cholangiocarcinoma and other biliary tract cancers.

CME information and select publications here.

Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.

CME information and select publications here.

Dr Arvind Dasari, Dr Van Morris, Dr Jenny Seligmann, Prof Eric Van Cutsem and moderator Dr Christopher Lieu summarize research findings guiding the application of biomarker-driven therapy for patients with colorectal cancers during a session at the 2025 ASCO Gastrointestinal Cancers Symposium.

CME information and select publications here.

Dr Surbhi Sidana from Stanford University in California discusses recent updates on chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma.

CME information and select publications here.

Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices.

CME information and select publications here.